A trial looking at brivanib and sorafenib for advanced liver cancer (BRISK-FL)

This trial compared brivanib with sorafenib as treatment for a type of liver cancer called hepatocellular carcinoma (HCC).

Doctors use a number of different treatments for HCC, including biological therapy. Both sorafenib and brivanib are types of biological therapy called cancer growth blockers. They stop signals that cancer cells use to divide and grow.

When this trial was done, sorafenib was being used to treat some people with HCC. Doctors wanted to find out if brivanib was also a useful treatment for people with advanced HCC.

The aims of this trial were to

• See if brivanib works as well as or better than sorafenib for people with advanced HCC

• Compare how each drug affects quality of life